Impact of Bi-26 Supplementation on Weight Gain in Underweight Infants
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Bi-26 (Strain of Bifidobacterium Longum, B. Infantis) Supplementation Versus Placebo on Weight Gain in Underweight Infants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Gates MRI
- Phone Number: +1 857 702 2108
- Email: clinical.trials@gatesmri.org
Study Contact Backup
- Name: Gates MRI (Toll Free Number)
- Phone Number: +1 866 789 5767
Study Locations
-
-
Islamabad Capital Territory
-
Islamabad, Islamabad Capital Territory, Pakistan, 44000
- Medical Facility A
-
Islamabad, Islamabad Capital Territory, Pakistan, 44000
- Medical Facility B
-
Islamabad, Islamabad Capital Territory, Pakistan, 44000
- Medical Facility C
-
-
Punjab
-
Lahore, Punjab, Pakistan, 54000
- Medical facility
-
Rawalpindi, Punjab, Pakistan, 46000
- Medical facility
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant must be between 30 days and 120 days of age (inclusive), at the time of enrollment (study Day 1)
- Hospitalized for acute non-surgical illness
- Completed acute stabilization phase of treatment, including fluid rehydration and antibiotic course, prior to enrollment (study Day 1)
- WAZ at enrollment (study Day 1) is less than negative 2 (<-2)
- Any sex
- Participant's parent(s)/legal guardian is capable of giving informed consent which includes agreement to comply with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
- Participant's parent(s)/legal guardian agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and have no current plans to relocate from the study area for the duration of the study
- Participant's parent(s)/legal guardian has easy access to reliable refrigeration (for storage of investigational product)
- Participant receives some feedings from breastmilk and mother intends to continue breastfeeding.
Exclusion Criteria:
- Congenital condition (suspected or confirmed) that the investigator considers likely to interfere with feeding or with normal growth and development
- Infant has not been discharged from hospital since birth or has not been at home for at least one week since birth
- Infant hospitalized with septic shock during current hospitalization
- Infant required mechanical ventilation during current hospitalization
- Infant with acute kidney injury on hospital admission
- Infant with severe jaundice and suspected kernicterus
- Infant receiving treatment for suspected or confirmed tuberculosis, or suspected or confirmed human immunodeficiency virus (HIV) infection
- Ongoing infant antibiotic (e.g. as prophylaxis in sickle cell disease) and/or probiotic usage
- Ongoing maternal antibiotic and/or probiotic usage for breast-feeding infants
- Inability of participant's parent(s)/legal guardian to comply with protocol requirements, as per investigator assessment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Bi-26 supplementation
Bi-26 administered daily.
|
A once-daily oral dose of Bi-26 will be provided to infants for 28 days.
|
|
Placebo Comparator: Placebo
Maltodextrin: Placebo administered daily
|
A once-daily oral dose of placebo maltodextrin will be provided to infants for 28 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Weight-for-age Z Score (WAZ) at Day 56
Time Frame: Baseline (Day 1) to Day 56
|
The Weight-for-Age Z-score (WAZ) is an anthropometric measure used to classify a child's nutritional status.
The WAZ measures the number of standard deviations of a child's actual weight from the median weight of children of the same age based on the World Health Organization (WHO) child growth standards (reference population).
WAZ of 0 represents the median weight for age in the reference population.
WAZ ≥-3 to <-2 standard deviations below the WHO child growth standards median is considered moderately underweight and WAZ <-3 is considered severely underweight.
Least Squares Mean, 95% Confidence Interval, and p-value was derived from mixed model repeated measures with treatment and visit as factors and baseline WAZ, baseline age (days), and study intervention compliance as covariates.
The treatment*visit interaction terms were included and used to estimate the adjusted mean difference in Change from Baseline in WAZ between Bi-26 and Placebo.
|
Baseline (Day 1) to Day 56
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Weight to Day 56
Time Frame: Baseline (Day 1) to Day 56
|
Weight (grams) was summarized using descriptive statistics.
Baseline (Day 1) was defined as the last available value prior to the participant receiving the first dose of the study intervention.
Change from Baseline was defined as post-dose visit value minus Baseline value.
|
Baseline (Day 1) to Day 56
|
|
Change From Baseline in WAZ Over Time Through Day 90
Time Frame: Baseline (Day 1) to Day 90
|
The Weight-for-Age Z-score (WAZ) is an anthropometric measure used to classify a child's nutritional status.
The WAZ measures the number of standard deviations of a child's actual weight from the median weight of children of the same age based on the World Health Organization (WHO) child growth standards (reference population).
WAZ of 0 represents the median weight for age in the reference population.
WAZ ≥-3 to <-2 standard deviations below the WHO child growth standards median is considered moderately underweight and WAZ <-3 is considered severely underweight.
Least Squares Mean, 95% Confidence Interval, and p-value was derived from mixed model repeated measures with treatment and visit as factors and baseline WAZ, baseline age (days), and study intervention compliance as covariates.
The treatment*visit interaction terms were included and used to estimate the adjusted mean difference in Change from Baseline in WAZ between Bi-26 and Placebo.
|
Baseline (Day 1) to Day 90
|
|
Percentage of Participants With a ≥ 0.3, ≥ 0.4, and ≥ 0.5 Change in WAZ From Baseline at Day 56
Time Frame: Baseline (Day 1) to Day 56
|
The Weight-for-Age Z-score (WAZ) is an anthropometric measure used to classify a child's nutritional status.
The WAZ measures the number of standard deviations of a child's actual weight from the median weight of children of the same age based on the World Health Organization (WHO) child growth standards (reference population).
WAZ of 0 represents the median weight for age in the reference population.
WAZ ≥-3 to <-2 standard deviations below the WHO child growth standards median is considered moderately underweight and WAZ <-3 is considered severely underweight.
|
Baseline (Day 1) to Day 56
|
|
Percentage of Participants Who Achieved a Score of WAZ > -2 at Day 56
Time Frame: At Day 56
|
The Weight-for-Age Z-score (WAZ) is an anthropometric measure used to classify a child's nutritional status.
The WAZ measures the number of standard deviations of a child's actual weight from the median weight of children of the same age based on the World Health Organization (WHO) child growth standards (reference population).
WAZ of 0 represents the median weight for age in the reference population.
WAZ ≥-3 to <-2 standard deviations below the WHO child growth standards median is considered moderately underweight and WAZ <-3 is considered severely underweight.
|
At Day 56
|
|
Percentage of Participants Re-hospitalized
Time Frame: Baseline to Day 56
|
Hospitalizations are due to acute non-surgical illness.
Percentage of participants re-hospitalized at Day 56 has been presented
|
Baseline to Day 56
|
|
Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Time Frame: Up to Day 90
|
An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE is considered treatment emergent if it started on or after the date of first dose of study intervention administration.
Serious TEAE is any untoward medical occurrences at any dose of study medication that: results in death; is life threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect and is an important medical event.
|
Up to Day 90
|
|
Percentage of Participants With Presence of B. Infantis in Stool
Time Frame: At Days 1, 28, 56 and 90
|
Stool samples were collected at defined time points to analyze the present of B.infantis.
|
At Days 1, 28, 56 and 90
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Gates MRI, Bill & Melinda Gates Medical Research Institute
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Gates MRI-MNK01-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.